[8-K] HCW Biologics Inc. Reports Material Event
HCW Biologics held its 2025 Annual Meeting of Stockholders on June 17, 2025, marked by technical difficulties with their service provider Broadridge Financial Solutions that affected virtual attendance. Despite these issues, the meeting achieved a quorum through in-person and proxy attendance.
Key developments include:
- Director Resignation: Gary M. Winer resigned from the Board of Directors immediately after the meeting. His resignation was not due to any disagreements with company operations or policies
- Director Election Results: Scott T. Garrett was successfully elected as Class I director with 534,541 votes in favor, while Gary M. Winer received significantly less support with only 133,365 votes in favor
- Auditor Appointment: Stockholders ratified Crowe LLP as the independent registered public accounting firm with overwhelming support (693,874 votes in favor)
To address the technical issues, the company will provide stockholders access to meeting replay until June 2026 and accept questions through July 31, 2025, via email at [email protected].
HCW Biologics ha tenuto la sua Assemblea Annuale degli Azionisti 2025 il 17 giugno 2025, caratterizzata da problemi tecnici con il fornitore di servizi Broadridge Financial Solutions che hanno influenzato la partecipazione virtuale. Nonostante queste difficolt脿, l'assemblea ha raggiunto il quorum grazie alla partecipazione in presenza e per delega.
Sviluppi chiave includono:
- Dimissioni del Direttore: Gary M. Winer si 猫 dimesso dal Consiglio di Amministrazione subito dopo l'assemblea. Le sue dimissioni non sono state causate da disaccordi sulle operazioni o politiche aziendali.
- Risultati delle Elezioni dei Direttori: Scott T. Garrett 猫 stato eletto con successo come direttore di Classe I con 534.541 voti favorevoli, mentre Gary M. Winer ha ricevuto un sostegno significativamente inferiore con soli 133.365 voti favorevoli.
- Nomina del Revisore: Gli azionisti hanno ratificato Crowe LLP come societ脿 di revisione contabile indipendente con un ampio sostegno (693.874 voti favorevoli).
Per risolvere i problemi tecnici, la societ脿 fornir脿 agli azionisti l'accesso alla registrazione dell'assemblea fino a giugno 2026 e accetter脿 domande via email all'indirizzo [email protected] fino al 31 luglio 2025.
HCW Biologics celebr贸 su Reuni贸n Anual de Accionistas 2025 el 17 de junio de 2025, marcada por dificultades t茅cnicas con su proveedor de servicios Broadridge Financial Solutions que afectaron la asistencia virtual. A pesar de estos problemas, la reuni贸n alcanz贸 el qu贸rum mediante asistencia presencial y por poder.
Los desarrollos clave incluyen:
- Renuncia de Director: Gary M. Winer renunci贸 a la Junta Directiva inmediatamente despu茅s de la reuni贸n. Su renuncia no se debi贸 a desacuerdos con las operaciones o pol铆ticas de la empresa.
- Resultados de la Elecci贸n de Directores: Scott T. Garrett fue elegido con 茅xito como director de Clase I con 534,541 votos a favor, mientras que Gary M. Winer recibi贸 un apoyo significativamente menor con solo 133,365 votos a favor.
- Nombramiento del Auditor: Los accionistas ratificaron a Crowe LLP como la firma independiente de contabilidad p煤blica registrada con un apoyo abrumador (693,874 votos a favor).
Para solucionar los problemas t茅cnicos, la compa帽铆a proporcionar谩 a los accionistas acceso a la repetici贸n de la reuni贸n hasta junio de 2026 y aceptar谩 preguntas hasta el 31 de julio de 2025, a trav茅s del correo electr贸nico [email protected].
HCW Biologics電� 2025雲� 6鞗� 17鞚� 2025雲� 鞐半 欤检＜齑濏殞毳� 臧滌禍頄堨溂氅�, 靹滊箘鞀� 鞝滉车鞐呾泊鞚� Broadridge Financial Solutions鞚� 旮办垹鞝� 氍胳牅搿� 鞚疙暣 臧�靸� 彀胳劃鞐� 鞏措牑鞗�鞚� 鞛堨棃鞀惦媹雼�. 鞚措煬頃� 氍胳牅鞐愲弰 攵堦惮頃橁碃, 須岇潣電� 歆侅爲 彀胳劃瓿� 鞙勳瀯 彀胳劃鞚� 韱淀暣 鞝曥”靾橂ゼ 頇曤炒頄堨姷雼堧嫟.
欤检殧 雮挫毄鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:
- 鞚挫偓 靷瀯: Gary M. Winer電� 須岇潣 歆來泟 鞚挫偓須岇棎靹� 靷瀯頄堨姷雼堧嫟. 攴胳潣 靷瀯鞚� 須岇偓 鞖挫榿鞚措倶 鞝曥眳鞐� 雽�頃� 鞚搓铂 霑岆鞚� 鞎勲嫏雼堧嫟.
- 鞚挫偓 靹犾稖 瓴瓣臣: Scott T. Garrett臧� 韥措灅鞀� I 鞚挫偓搿� 靹标车鞝侅溂搿� 靹犾稖霅橃棃鞙茧┌ 534,541响�鞚� 彀劚鞚� 氚涭晿鞀惦媹雼�. 氚橂┐ Gary M. Winer電� 133,365响�搿� 頉敩 鞝侅潃 歆�歆�毳� 氚涭晿鞀惦媹雼�.
- 臧愳偓鞚� 靹犾瀯: 欤检＜霌れ潃 Crowe LLP毳� 霃呺 霌彪 瓿奠澑 須岅硠氩曥澑鞙茧 鞎曤弰鞝侅澑 彀劚(693,874响�)鞙茧 鞀轨澑頄堨姷雼堧嫟.
旮办垹鞝� 氍胳牅毳� 頃搓舶頃橁赴 鞙勴暣 須岇偓電� 欤检＜霌れ棎瓴� 2026雲� 6鞗旉箤歆� 須岇潣 鞛儩 鞝戧芳 甓岉暅鞚� 鞝滉车頃橁碃, 2025雲� 7鞗� 31鞚缄箤歆� [email protected] 鞚措⿺鞚检潉 韱淀暣 歆堧鞚� 氚涭潉 鞓堨爼鞛呺媹雼�.
HCW Biologics a tenu son Assembl茅e Annuelle des Actionnaires 2025 le 17 juin 2025, marqu茅e par des difficult茅s techniques avec leur fournisseur de services Broadridge Financial Solutions qui ont affect茅 la participation virtuelle. Malgr茅 ces probl猫mes, la r茅union a atteint le quorum gr芒ce 脿 la pr茅sence physique et aux procurations.
Les faits marquants incluent :
- D茅mission d'un administrateur : Gary M. Winer a d茅missionn茅 du conseil d'administration imm茅diatement apr猫s la r茅union. Sa d茅mission n'茅tait pas due 脿 des d茅saccords avec les op茅rations ou les politiques de l'entreprise.
- R茅sultats de l'茅lection des administrateurs : Scott T. Garrett a 茅t茅 茅lu avec succ猫s administrateur de la Classe I avec 534 541 voix en sa faveur, tandis que Gary M. Winer a re莽u un soutien nettement moindre avec seulement 133 365 voix en sa faveur.
- Nomination de l'auditeur : Les actionnaires ont ratifi茅 Crowe LLP en tant que cabinet comptable ind茅pendant enregistr茅 avec un soutien 茅crasant (693 874 voix en faveur).
Pour rem茅dier aux probl猫mes techniques, la soci茅t茅 offrira aux actionnaires un acc猫s au replay de la r茅union jusqu'en juin 2026 et acceptera les questions par e-mail 脿 [email protected] jusqu'au 31 juillet 2025.
HCW Biologics hielt am 17. Juni 2025 seine Jahreshauptversammlung 2025 ab, die von technischen Schwierigkeiten mit dem Dienstleister Broadridge Financial Solutions gepr盲gt war, welche die virtuelle Teilnahme beeintr盲chtigten. Trotz dieser Probleme wurde das Quorum durch pers枚nliche und Stimmrechtsvertretung erreicht.
Wichtige Entwicklungen umfassen:
- R眉cktritt eines Direktors: Gary M. Winer trat unmittelbar nach der Versammlung aus dem Vorstand zur眉ck. Sein R眉cktritt war nicht auf Meinungsverschiedenheiten bez眉glich der Unternehmensf眉hrung oder -politik zur眉ckzuf眉hren.
- Ergebnisse der Direktorenwahl: Scott T. Garrett wurde erfolgreich als Direktor der Klasse I mit 534.541 Stimmen gew盲hlt, w盲hrend Gary M. Winer mit nur 133.365 Stimmen deutlich weniger Unterst眉tzung erhielt.
- Bestellung des Wirtschaftspr眉fers: Die Aktion盲re ratifizierten Crowe LLP als unabh盲ngige registrierte Wirtschaftspr眉fungsgesellschaft mit 眉berw盲ltigender Mehrheit (693.874 Stimmen).
Um die technischen Probleme zu beheben, wird das Unternehmen den Aktion盲ren bis Juni 2026 Zugang zur Wiederholung der Versammlung gew盲hren und Fragen bis zum 31. Juli 2025 per E-Mail an [email protected] entgegennehmen.
- Scott T. Garrett received strong shareholder support with 98.3% of votes cast in favor of his election as Class I director
- Appointment of Crowe LLP as independent auditor was overwhelmingly approved with 99.9% of votes in favor
- Director Gary M. Winer resigned from the Board immediately after receiving significantly low shareholder support (only 24.4% votes 'For' vs 75.6% 'Withheld')
- Technical difficulties during the Annual Meeting prevented some stockholders from accessing the virtual meeting platform, indicating potential governance and communication issues
Insights
Director Winer resigned after receiving 75% opposition votes; board seat will remain vacant following this significant shareholder rebuke.
This 8-K reveals a substantial corporate governance development at HCW Biologics. Director Gary Winer resigned immediately following the Annual Meeting where he received an overwhelming rejection from shareholders - just 133,365 votes "For" compared to 410,361 votes "Withheld" (a 75% opposition rate). This level of shareholder dissent is highly unusual in board elections and represents a clear vote of no confidence.
The contrast with fellow nominee Scott Garrett is striking - Garrett received 534,541 votes "For" with only 9,185 "Withheld" (98% approval). While the filing includes standard language that Winer's departure "was not due to any disagreement" with the company, the timing immediately following such decisive shareholder rejection speaks volumes.
Notably, the board has chosen not to fill the vacant seat, which effectively reduces the board's size. This decision could impact board dynamics, committee structures, and overall oversight capabilities. For an emerging growth company like HCW Biologics, board composition is particularly critical during development stages.
The filing also mentions technical difficulties with Broadridge's virtual meeting platform that may have prevented some shareholders from participating, though a quorum was achieved. This raises minor concerns about shareholder access to governance processes, though the company is providing alternative means for information access and question submission.
HCW Biologics ha tenuto la sua Assemblea Annuale degli Azionisti 2025 il 17 giugno 2025, caratterizzata da problemi tecnici con il fornitore di servizi Broadridge Financial Solutions che hanno influenzato la partecipazione virtuale. Nonostante queste difficolt脿, l'assemblea ha raggiunto il quorum grazie alla partecipazione in presenza e per delega.
Sviluppi chiave includono:
- Dimissioni del Direttore: Gary M. Winer si 猫 dimesso dal Consiglio di Amministrazione subito dopo l'assemblea. Le sue dimissioni non sono state causate da disaccordi sulle operazioni o politiche aziendali.
- Risultati delle Elezioni dei Direttori: Scott T. Garrett 猫 stato eletto con successo come direttore di Classe I con 534.541 voti favorevoli, mentre Gary M. Winer ha ricevuto un sostegno significativamente inferiore con soli 133.365 voti favorevoli.
- Nomina del Revisore: Gli azionisti hanno ratificato Crowe LLP come societ脿 di revisione contabile indipendente con un ampio sostegno (693.874 voti favorevoli).
Per risolvere i problemi tecnici, la societ脿 fornir脿 agli azionisti l'accesso alla registrazione dell'assemblea fino a giugno 2026 e accetter脿 domande via email all'indirizzo [email protected] fino al 31 luglio 2025.
HCW Biologics celebr贸 su Reuni贸n Anual de Accionistas 2025 el 17 de junio de 2025, marcada por dificultades t茅cnicas con su proveedor de servicios Broadridge Financial Solutions que afectaron la asistencia virtual. A pesar de estos problemas, la reuni贸n alcanz贸 el qu贸rum mediante asistencia presencial y por poder.
Los desarrollos clave incluyen:
- Renuncia de Director: Gary M. Winer renunci贸 a la Junta Directiva inmediatamente despu茅s de la reuni贸n. Su renuncia no se debi贸 a desacuerdos con las operaciones o pol铆ticas de la empresa.
- Resultados de la Elecci贸n de Directores: Scott T. Garrett fue elegido con 茅xito como director de Clase I con 534,541 votos a favor, mientras que Gary M. Winer recibi贸 un apoyo significativamente menor con solo 133,365 votos a favor.
- Nombramiento del Auditor: Los accionistas ratificaron a Crowe LLP como la firma independiente de contabilidad p煤blica registrada con un apoyo abrumador (693,874 votos a favor).
Para solucionar los problemas t茅cnicos, la compa帽铆a proporcionar谩 a los accionistas acceso a la repetici贸n de la reuni贸n hasta junio de 2026 y aceptar谩 preguntas hasta el 31 de julio de 2025, a trav茅s del correo electr贸nico [email protected].
HCW Biologics電� 2025雲� 6鞗� 17鞚� 2025雲� 鞐半 欤检＜齑濏殞毳� 臧滌禍頄堨溂氅�, 靹滊箘鞀� 鞝滉车鞐呾泊鞚� Broadridge Financial Solutions鞚� 旮办垹鞝� 氍胳牅搿� 鞚疙暣 臧�靸� 彀胳劃鞐� 鞏措牑鞗�鞚� 鞛堨棃鞀惦媹雼�. 鞚措煬頃� 氍胳牅鞐愲弰 攵堦惮頃橁碃, 須岇潣電� 歆侅爲 彀胳劃瓿� 鞙勳瀯 彀胳劃鞚� 韱淀暣 鞝曥”靾橂ゼ 頇曤炒頄堨姷雼堧嫟.
欤检殧 雮挫毄鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:
- 鞚挫偓 靷瀯: Gary M. Winer電� 須岇潣 歆來泟 鞚挫偓須岇棎靹� 靷瀯頄堨姷雼堧嫟. 攴胳潣 靷瀯鞚� 須岇偓 鞖挫榿鞚措倶 鞝曥眳鞐� 雽�頃� 鞚搓铂 霑岆鞚� 鞎勲嫏雼堧嫟.
- 鞚挫偓 靹犾稖 瓴瓣臣: Scott T. Garrett臧� 韥措灅鞀� I 鞚挫偓搿� 靹标车鞝侅溂搿� 靹犾稖霅橃棃鞙茧┌ 534,541响�鞚� 彀劚鞚� 氚涭晿鞀惦媹雼�. 氚橂┐ Gary M. Winer電� 133,365响�搿� 頉敩 鞝侅潃 歆�歆�毳� 氚涭晿鞀惦媹雼�.
- 臧愳偓鞚� 靹犾瀯: 欤检＜霌れ潃 Crowe LLP毳� 霃呺 霌彪 瓿奠澑 須岅硠氩曥澑鞙茧 鞎曤弰鞝侅澑 彀劚(693,874响�)鞙茧 鞀轨澑頄堨姷雼堧嫟.
旮办垹鞝� 氍胳牅毳� 頃搓舶頃橁赴 鞙勴暣 須岇偓電� 欤检＜霌れ棎瓴� 2026雲� 6鞗旉箤歆� 須岇潣 鞛儩 鞝戧芳 甓岉暅鞚� 鞝滉车頃橁碃, 2025雲� 7鞗� 31鞚缄箤歆� [email protected] 鞚措⿺鞚检潉 韱淀暣 歆堧鞚� 氚涭潉 鞓堨爼鞛呺媹雼�.
HCW Biologics a tenu son Assembl茅e Annuelle des Actionnaires 2025 le 17 juin 2025, marqu茅e par des difficult茅s techniques avec leur fournisseur de services Broadridge Financial Solutions qui ont affect茅 la participation virtuelle. Malgr茅 ces probl猫mes, la r茅union a atteint le quorum gr芒ce 脿 la pr茅sence physique et aux procurations.
Les faits marquants incluent :
- D茅mission d'un administrateur : Gary M. Winer a d茅missionn茅 du conseil d'administration imm茅diatement apr猫s la r茅union. Sa d茅mission n'茅tait pas due 脿 des d茅saccords avec les op茅rations ou les politiques de l'entreprise.
- R茅sultats de l'茅lection des administrateurs : Scott T. Garrett a 茅t茅 茅lu avec succ猫s administrateur de la Classe I avec 534 541 voix en sa faveur, tandis que Gary M. Winer a re莽u un soutien nettement moindre avec seulement 133 365 voix en sa faveur.
- Nomination de l'auditeur : Les actionnaires ont ratifi茅 Crowe LLP en tant que cabinet comptable ind茅pendant enregistr茅 avec un soutien 茅crasant (693 874 voix en faveur).
Pour rem茅dier aux probl猫mes techniques, la soci茅t茅 offrira aux actionnaires un acc猫s au replay de la r茅union jusqu'en juin 2026 et acceptera les questions par e-mail 脿 [email protected] jusqu'au 31 juillet 2025.
HCW Biologics hielt am 17. Juni 2025 seine Jahreshauptversammlung 2025 ab, die von technischen Schwierigkeiten mit dem Dienstleister Broadridge Financial Solutions gepr盲gt war, welche die virtuelle Teilnahme beeintr盲chtigten. Trotz dieser Probleme wurde das Quorum durch pers枚nliche und Stimmrechtsvertretung erreicht.
Wichtige Entwicklungen umfassen:
- R眉cktritt eines Direktors: Gary M. Winer trat unmittelbar nach der Versammlung aus dem Vorstand zur眉ck. Sein R眉cktritt war nicht auf Meinungsverschiedenheiten bez眉glich der Unternehmensf眉hrung oder -politik zur眉ckzuf眉hren.
- Ergebnisse der Direktorenwahl: Scott T. Garrett wurde erfolgreich als Direktor der Klasse I mit 534.541 Stimmen gew盲hlt, w盲hrend Gary M. Winer mit nur 133.365 Stimmen deutlich weniger Unterst眉tzung erhielt.
- Bestellung des Wirtschaftspr眉fers: Die Aktion盲re ratifizierten Crowe LLP als unabh盲ngige registrierte Wirtschaftspr眉fungsgesellschaft mit 眉berw盲ltigender Mehrheit (693.874 Stimmen).
Um die technischen Probleme zu beheben, wird das Unternehmen den Aktion盲ren bis Juni 2026 Zugang zur Wiederholung der Versammlung gew盲hren und Fragen bis zum 31. Juli 2025 per E-Mail an [email protected] entgegennehmen.
FAQ
Why did Gary M. Winer resign from HCWB's Board of Directors in June 2025?
What were the voting results for HCWB's director elections at the 2025 Annual Meeting?
What technical issues occurred during HCWB's 2025 Annual Meeting?
How can HCWB shareholders access the 2025 Annual Meeting replay and submit questions?
Did HCWB shareholders approve their independent auditor for fiscal year 2025?
